by admin | Nov 18, 2019 | Licensing
Merck, a leading science and technology company, announced that it has signed a license agreement providing Evotec SE access to Merck’s foundational CRISPR intellectual property. Evotec, an international biotechnology company headquartered in Hamburg, Germany,...
by admin | Sep 7, 2019 | Licensing
InterCure announced that subsidiary Canndoc has entered into a strategic distribution agreement with Salomon, Levin, Elstein (S.L.E.,) which is owned by Teva Pharmaceuticals Industries. Under terms of the agreement, S.L.E. will distribute Canndoc’s GMP products...
by admin | Aug 13, 2019 | Licensing
Novartis AG’s small molecule phosphoinositide 3-kinase delta (PI3Kẟ) blocker CDZ173, which is in a registration-enabling study, is expected to reach the market in 2022 lastest. Activated Phosphoinositide 3-kinase Delta Syndrome (APDS) is an ultra-rare, debilitating...
